Chemotherapy remains the mainstay treatment for aggressive breast cancer subtypes such as triple-negative breast cancer (TNBC). It has been recognized that some chemotherapeutics besides being cytotoxic to tumor cells, also induce immunomodulatory effects that can stimulate tumor cell killing. We aimed to in-depth investigate this presumed chemotherapy-induced immunomodulation in TNBC, focusing on the platinum-based agent cisplatin and using an in-house characterized immunocompetent intraductal mouse model. Our model relies on the injection of 4T1 triple-negative mammary tumor cells in syngeneic lactating mice, representing TNBC progression from early ductal carcinoma in situ/DCIS to late invasive carcinoma/IC stages. As soon as primary tum...
Objective(s): Immune checkpoint expression on tumor-infiltrating lymphocytes (TILs) has a correlatio...
Triple negative breast cancer (TNBC) is a highly heterogeneous tumor. There is increasing evidence o...
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected tr...
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype showing limited immunoth...
Aggressive triple-negative breast cancer (TNBC) is classically treated with chemotherapy. Besides di...
Cytotoxic cisplatin chemotherapy has a direct killing effect on tumor cells and significantly modula...
The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in th...
The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in th...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
The intraductal model for breast cancer allows to investigate the human disease process from early d...
The intraductal model for breast cancer allows to investigate the human disease process from early d...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
Triple-negative breast cancer (TNBC) is primarily treated via chemotherapy; in parallel, efforts are...
Objective(s): Immune checkpoint expression on tumor-infiltrating lymphocytes (TILs) has a correlatio...
Triple negative breast cancer (TNBC) is a highly heterogeneous tumor. There is increasing evidence o...
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected tr...
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype showing limited immunoth...
Aggressive triple-negative breast cancer (TNBC) is classically treated with chemotherapy. Besides di...
Cytotoxic cisplatin chemotherapy has a direct killing effect on tumor cells and significantly modula...
The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in th...
The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in th...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
The intraductal model for breast cancer allows to investigate the human disease process from early d...
The intraductal model for breast cancer allows to investigate the human disease process from early d...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
Epithelial ovarian cancer (EOC) is an immunologically active malignancy, but thus far immune therapy...
Triple-negative breast cancer (TNBC) is primarily treated via chemotherapy; in parallel, efforts are...
Objective(s): Immune checkpoint expression on tumor-infiltrating lymphocytes (TILs) has a correlatio...
Triple negative breast cancer (TNBC) is a highly heterogeneous tumor. There is increasing evidence o...
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected tr...